tbuckley/cabot-search huggingface dataset:
A comparison of chemotherapy-induced peripheral neuropathy assessment tools in patients receiving neurotoxic chemotherapy.
Authors: Sabrina Ramnarine, Linda J Williams, Patrick M. Dougherty, Marie T Fallon
Journal: Journal of Clinical Oncology (2016)

132 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a challenging toxicity with significant sequelae impacting prognosis and quality of life. Clinical presentation although predominantly sensory can include motor and autonomic dysfunction. As there is no standardised approach to the diagnosis and assessment of CIPN, characterisation of symptoms can be problematic. This study aims to investigate the relationship between various CIPN assessment tools in gynaecological, colorectal and lung cancer patients receiving neurotoxic chemotherapy. Methods: Patients with the above cancers receiving chemotherapy (platinum and/or taxanes) were assessed prospectively every 3 weeks for a cumulative total of 159 cycles. Prior to each cycle the following tools were utilised: European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 questionnaire, MD Anderson Symptom Inventory (MDASI) and associated descriptors of sensory disturbance/pain. Spearman’s correlation coefficients were used to compare these tools with the most commonly measured CIPN diagnostic tool, the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE). Results: The EORTC sensory, motor subscales and total scores were highly correlated as expected. MDASI, question 13 (severity of numbness or tingling at its worst) was most correlated with the EORTC sensory subscale (ρ = 0.76). The correlation between the descriptors and EORTC sensory improved (ρ = 0.64 to ρ = 0.71) when the analysis focused on only numbness or tingling. CTCAE grade was more highly correlated with EORTC sensory (ρ = 0.61) and descriptors (ρ = 0.76) compared with EORTC motor (ρ = 0.46). All correlations were statistically significant (p &lt; 0.001). Conclusions: In this mixed cohort of patients, comparison of the various CIPN assessment tools during chemotherapy cycles revealed significant correlations. This suggests the tools are useful in capturing the predominance of sensory symptoms and characterising the sensation of numbness and tingling. Further evaluation of this cohort along with additional studies may provide insight regarding the optimum choice of assessment tool(s).
Outdoor exposure to formaldehyde (CH2O) is associated with an increased risk of hospitalization for respiratory diseases in children
Authors: Roberto de Marco, Pierpaolo Marchetti, Paolo Girardi, Maria Enrica Fracasso, Linda Guarda, Alessandro Marcon, Vanda Pironi, Giorgio Siliprandi, Paolo Ricci
Journal: European Respiratory Journal (2011)

Background: Children living near wood industries have an increased risk of developing respiratory diseases.

Objectives: To assess if residential outdoor exposure to NO2 and CH2O was associated with the risk of hospitalization for respiratory diseases in children.

Methods: In 2006, all the children (3-14 years) living in the Viadana district (the largest wood manufacturing area in Northern Italy) were surveyed through a parental questionnaire (n=3854) and their home addresses were geocoded. Their history of hospitalization for respiratory diseases (ICD-IX: 460-519) was assessed from January 2007 to December 2009, using discharge records obtained from the local Health Unit. To assess the outdoor exposure to NO2 and CH2O, 63 passive samplers were installed in the area using a Partitioning Around Medoids (PAM) algorithm. Pollutants were monitored twice, both in winter and in summer 2010. Kriging interpolation was used to attribute the average annual concentration of pollutants to each child. Poisson regression models were used to assess the association between the hospitalization rates (HR) and the average concentration of pollutants.

Results: By December 2010, 3798 (98.5%) children had been traced. During the 3 years of follow-up, 121 hospital admissions, caused by respiratory diseases, occurred (annual HR = 10.8/1000/year). The HR for respiratory diseases slightly increased with increasing outdoor exposure to NO2 (μg/m3) (RR:1.02; 95%CI: 0.95-1.10), while they were strongly associated to CH2O outdoor concentration (μg/m3) (RR:2.41; 95%CI: 1.07-5.43).

Conclusions: Emissions from wood industries apparently have a serious impact on children's health.
ANF-Rho: A Dose-Ranging Phase I Study to Determine Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
Authors: Deven V. Parmar, Daniel Byczkowski, Ronald G. Jubin, Abraham Abuchowski, Peter Buontempo, Gerry Gitlin, Michelle Boro, Hemant K. Misra
Journal: Blood (2015)
Can Cardiac Conduction System Disease Be Prevented?
Authors: Sanjiv M. Narayan, Tina Baykaner, David J. Maron
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
C4-06: Photodynamic therapy using talaporfin sodium (NPe6) for centrally located early stage lung cancer
Authors: Jitsuo Usuda, Hidetoshi Honda, Shuji Ichinose, Takeshi Hirata, Tatsuya Inoue, Keishi Ohtani, Sachio Maehara, Norihiko Ikeda, Kinya Furukawa, Tetsuya Okunaka, Harubumi Kato
Journal: Journal of Thoracic Oncology (2007)
P-102 Sorafenib after locoregional treatments for advanced or recurrent hepatocellular carcinoma
Authors: C. Ribeiro, J. Barreira, A. Parmanande, P. Semedo, M. Semedo, M. Silva, N. Costa, V. Ribeiro, E. Coimbra, E. Barroso
Journal: Annals of Oncology (2016)
Lateral Membrane-Specific MAGUK CASK Down-Regulates Na <sub>V</sub> 1.5 Channel in Cardiac Myocytes
Authors: Catherine A. Eichel, Adeline Beuriot, Morgan Y.E. Chevalier, Jean-Sébastien Rougier, Florent Louault, Gilles Dilanian, Julien Amour, Alain Coulombe, Hugues Abriel, Stéphane N. Hatem, Elise Balse
Journal: Circulation Research (2016)

Mechanisms underlying membrane protein localization are crucial in the proper function of cardiac myocytes. The main cardiac sodium channel, NaV1.5, carries the sodium current (INa) that provides a rapid depolarizing current during the upstroke of the action potential. Although enriched in the intercalated disc, NaV1.5 is present in different membrane domains in myocytes and interacts with several partners.To test the hypothesis that the MAGUK (membrane-associated guanylate kinase) protein CASK (calcium/calmodulin-dependent serine protein kinase) interacts with and regulates NaV1.5 in cardiac myocytes.Immunostaining experiments showed that CASK localizes at lateral membranes of cardiac myocytes, in association with dystrophin. Whole-cell patch clamp showed that CASK-silencing increases INa in vitro. In vivo CASK knockdown similarly increased INa recorded in freshly isolated myocytes. Pull-down experiments revealed that CASK directly interacts with the C-terminus of NaV1.5. CASK silencing reduces syntrophin expression without affecting NaV1.5 and dystrophin expression levels. Total Internal Reflection Fluorescence microscopy and biotinylation assays showed that CASK silencing increased the surface expression of NaV1.5 without changing mRNA levels. Quantification of NaV1.5 expression at the lateral membrane and intercalated disc revealed that the lateral membrane pool only was increased upon CASK silencing. The protein transport inhibitor brefeldin-A prevented INa increase in CASK-silenced myocytes. During atrial dilation/remodeling, CASK expression was reduced but its localization remained unchanged.This study constitutes the first description of an unconventional MAGUK protein, CASK, which directly interacts with NaV1.5 channel and controls its surface expression at the lateral membrane by regulating ion channel trafficking.
Abstract P279: YAP, a Transcriptional Cofactor of the Hippo Pathway, Regulates Cardiomyocyte Growth, Survival, and Proliferation
Authors: Yanfei Yang, Noritsugu Nakano, Junichi Sadoshima
Journal: Circulation Research (2011)

Mst1 and Lats2, components of the mammalian Hippo pathway, stimulate apoptosis and inhibit hypertrophy of cardiomyocytes (CMs), thereby mediating reperfusion injury and heart failure. YAP, a transcription factor co-factor, is negatively regulated by the Hippo pathway, and controls cell survival, proliferation and tissue regeneration. The role of YAP in regulating growth and death of CMs is poorly understood. YAP overexpression in CMs induced cardiac hypertrophy, as indicated by increases in cell size (+1.2 fold, p&lt;0.01), protein content (+1.1 fold, p&lt;0.01) and ANF (luciferase reporter activity +1.7 fold, mRNA +2.2 fold, and staining +2.7 fold, p&lt;0.01). Lats2 phosphorylates YAP at Serine 127, which induces cytoplasmic translocation of YAP, whereas YAP(S127A) is localized constitutively in the nucleus. Expression of YAP(S127A) enhanced hypertrophy in cultured CMs compared to that of wild type YAP (+1.87 fold ANF staining, p&lt;0.05), suggesting that the Mst1/Hippo pathway negatively regulates cardiac hypertrophy through YAP. YAP inhibited cell death induced by H2O2 treatment, as evaluated with TUNEL staining (-65%, p&lt;0.05) and CellTiter Blue assays (+34.9%, p&lt;0.01), indicating that YAP plays an essential role in mediating CM survival. Interestingly, YAP also significantly increased Ki67 positive cells in cultured CMs compared to LacZ (+2.65 fold, p&lt;0.05). We used a mouse model of chronic myocardial infarction (MI) to evaluate the function of YAP in the heart in vivo. Although YAP is diffusely localized both in the nucleus and cytosol in CMs in control hearts, CMs in the border zone of MI exhibited nuclear localization of YAP whereas YAP was excluded from the nucleus in CMs in the remodeling area four days after MI (+6.52 fold and +1.28 fold). Some of the YAP positive CMs in the border zone exhibited positive co-staining with Ki67, suggesting that YAP potentially induces CM proliferation. A significant increase in nuclear YAP and Ki67 positive CMs (+2.95 fold, p&lt;0.01 and +2.18 fold, p&lt;0.05) was also observed in neonatal rat hearts whose apex was surgically resected three days before euthanasia. These results suggest that YAP plays an important role in mediating not only hypertrophy and survival, but also proliferation of CMs in response to myocardial injury.
American Cancer Society Guidelines for the Early Detection of Cancer
Authors: R. A. Smith, V. Cokkinides, A. C. von Eschenbach, B. Levin, C. Cohen, C. D. Runowicz, S. Sener, D. Saslow, H. J. Eyre
Journal: CA A Cancer Journal for Clinicians (2002)

Each year the American Cancer Society publishes a summary of existing recommendations for early cancer detection, including updates, and/or emerging issues that are relevant to screening for cancer. In last year's article, the guidelines regarding screening for the early detection of prostate, colorectal, and endometrial cancers were updated, as was the narrative pertaining to testing for early lung cancer detection. Although none of the ACS's guidelines were updated in 2001, work is proceeding on an update of screening recommendations for breast and cervical cancer and an update of these guidelines will be announced in the January/February 2003 issue of CA. As in previous issues, we review recommendations for the "cancer-related check-up," in which clinical encounters provide case-finding and health counseling opportunities. Finally, we provide an update of the most recent data pertaining to participation rates in cancer screening by age, gender, and ethnicity from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System (BRFSS) and National Health Interview Survey (NHIS).
Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group
Authors: Nigel S. Key, Alok A. Khorana, Nigel Mackman, Owen J.T. McCarty, Gilbert C. White, Charles W. Francis, Keith R. McCrae, Joseph S. Palumbo, Gary E. Raskob, Andrew T. Chan, Anil K. Sood
Journal: Cancer Research (2016)

The risk for venous thromboembolism (VTE) is increased in cancer and particularly with chemotherapy, and it portends poorer survival among patients with cancer. However, many fundamental questions about cancer-associated VTE, or Trousseau syndrome, remain unanswered. This report summarizes the proceedings of a working group assembled by the NCI and NHLBI in August 2014 to explore the state of the science in cancer-associated VTE, identify clinically important research gaps, and develop consensus on priorities for future research. Representing a convergence of research priorities between the two NIH Institutes, the workshop addressed epidemiologic, basic science, clinical, and translational issues in cancer-associated VTE. Cancer Res; 76(13); 3671-5. ©2016 AACR.
Response of Microbodies in Morris Hepatoma 9618A to Clofibrate2
Authors: Hideyuki Tsukada, Yohichi Mochizuki, Masayuki Itabashi, Mikio Gotoh, Harold P. Morris
Journal: JNCI Journal of the National Cancer Institute (1975)

Regulation of the formation of microbodies in Morris hepatoma 9618A was studied by examination of the response of the organelles to clofibrate. The fine structures of microbodies in the hepatoma cells closely resembled those in hepatocytes of normal adult rats. In clofibrate-treated rats, the tumor cells showed a slight increase in the size of microbodies and in catalase activity; however, the tumor microbodies did not increase in number. In contrast, in adult clofibrate-treated rats and rats on the day of birth whose mothers received clofibrate during the gestation period, the hepatocytes showed microbodies that were greater in both number and size, and the catalase activity in the liver was definitely elevated.
Acrokeratosis Paraneoplastica
Authors: Frank S van Leersum, Xiaomeng Liu
Journal: New England Journal of Medicine (2015)

A 66-year-old man presented to the clinic with a 4-week history of painful, edematous, and scaly ears, a condition that was later accompanied by itchy, hyperkeratotic plaques on the palms and soles. Bazex's syndrome (acrokeratosis paraneoplastica) was suspected.
Spina Ventosa
Authors: Ramón Baeza-Trinidad, Jose A Oteo Revuelta
Journal: New England Journal of Medicine (2015)

A 17-year-old boy was assessed because of a 2-month history of pain and swelling on his left hand. He had visited Pakistan 6 months earlier. On examination, a hard nodule was noted around the left third metacarpal. Staining of exudate from the third metacarpal showed acid-fast bacilli.
Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT
Authors: Benjamin Noto, Alexis Vrachimis, Michael Schäfers, Lars Stegger, Kambiz Rahbar
Journal: Clinical Nuclear Medicine (2016)

A 65-year-old man with disseminated bone metastases of prostate cancer was referred for Ga-PSMA-HBED-CC-PET/CT (short PSMA-PET/CT) to exclude visceral metastases before treatment of bone metastases with Ra-dichloride. Apart from disseminated bone metastases, PSMA-PET/CT revealed a focal cerebral tracer uptake in the right frontal lobe highly suspicious for cerebral spread. According to patient history, a cerebral infarction occurred 14 days before PSMA imaging in corresponding localization confirmed by MRI scanning. This case demonstrates the possibility of false-positive finding of cerebral metastases in PSMA-PET early after stroke.
Chromosomes of Tumor Cells. II. Effect of Various Liver Carcinogens on Mitosis of Hepatic Cells
Authors: M M MAINI, H F STICH
Journal: JNCI Journal of the National Cancer Institute (1961)

A comparative cytological study of the effects of various liver carcinogens and noncarcinogenic derivatives on mitosis was undertaken. S′-Methyl-4-dimethylaminoazobenzene (3′-Me-DAB) and thioacetamide (TAA) were chosen as substances of high carcinogenic activity; 4-monomethylaminoazobenzene(MAB) as a substance of moderate activity; o-aminoazotoluene (AAT), 4′-methyl-4-dimethylaminoazobenzene (4′-Me-DAB), ethionine, and thiourea as weak carcinogens; and 2-methyl-4-dimethylaminoazobenzene (2-Me-DAB) and 4-aminoazobenzene (AB) as two samples of noncarcinogenic azo dyes. Their ability to provoke a proliferation of hepatic tissue, to induce the formation of highly polyploid cells, and to cause mitotic irregularities was examined. A correlation existed between the carcinogenic activity of a substance and its ability to induce a proliferation and a relatively large number of mitotic irregularities in the precancerous liver, which lead to a genetically heterogeneous cell population. 2-Me-DAB is noncarcinogenic, although it can produce mitotic irregularities in the regenerating liver, because it lacks the ability to stimulate cell proliferation. AB induces neither a chromosome damage or proliferation. Thus, these noncarcinogenic azo dyes lack the ability to produce a genetically heterogeneous cell population in the liver. The type of mitotic irregularities, varying from chromosome fragmentation to incomplete spindle function, was similar in all precancerous livers independent of the molecular structure of the carcinogens used. The chromosome injury induced by the carcinogens can persist in a latent form over several months. It was concluded that hepatomas are only produced when both factors are present: an injury to the chromosomes and an active cell proliferation.
Global differences in cancer drug prices: A comparative analysis.
Authors: Daniel A. Goldstein, Jonathon Clark, Yifan Tu, Jie Zhang, Fenqi Fang, Robert Michael Goldstein, Salomon M. Stemmer, Eli Rosenbaum
Journal: Journal of Clinical Oncology (2016)

LBA6500 Background: Cancer drug prices are different in every country in the world, however, little is known about the magnitude of these differences. The primary objective of this study was to describe the differences in prices globally. The secondary objective was to understand ability to pay, using gross domestic product per capita at purchasing power parity (GDPcap), as a surrogate. Methods: We calculated monthly drug doses for 23 cancer drugs, 15 of which are available generically. We then calculated monthly drug prices from 6 countries on 5 different continents: Australia (AUS), China (CHI), India (IND), South Africa (SA), United Kingdom (UK), and United States (US). Given the lack of availability of discounted prices, we used list prices in order to make appropriate comparisons. Prices were obtained from locally and nationally recognized institutions. The monthly cost was converted to US$ at the exchange rate ruling on 19 January 2016. We obtained GDPcap data for each country from the International Monetary Fund, in order to estimate the monthly drug price as a percentage of GDPcap. Results: Results are displayed in the table. The median monthly patented drug price ranged from US$1515 (IND) to $8694 (US). The median monthly generic drug price ranged from US$120 (SA) to $654 (US). The median monthly % of GDPcap for patented drugs ranged from 71% (AUS) to 313% (IND). The median monthly % of GDPcap for generic drugs ranged from 3% (AUS) to 48% (CHI). Detailed information regarding specific drugs will be presented. Conclusions: There is a wide variation in drug prices globally. Despite lower prices in poorer countries, both generic and patented drugs appear to be less affordable in poorer countries. Price differences likely have some impact on access to care within individual countries. [Table: see text]
Submucosal carcinoma of the gastroesophageal junction diagnosed after peroral endoscopic myotomy
Authors: Dexter Chan, Dmitrii Dolgunov, Victor Lee, Philip Chiu, Jimmy So
Journal: Endoscopy (2015)

Gastroesophageal junction (GEJ) malignancies are found in 4.7 % of patients who fulfil the manometric criteria for achalasia [1]. Such malignancies may manifest as pseudoachalasia because of submucosal infiltration and secondary impairment of the inhibitory neurons of the esophageal myenteric plexus, therefore mimicking the manometric pattern of achalasia [2]. Despite endoscopic biopsies, false-negative rates of 25 % may mask this cause of pseudoachalasia [3].
Utilization and cost of mental illness coverage in the Federal Employees Health Benefits Program, 1973
Authors: E C Hustead, S S Sharfstein
Journal: American Journal of Psychiatry (1978)

The authors examine the utilization of mental illness benefits under the Blue Cross/Blue Shield and Aetna plans for federal employees; the latter plan sharply cut back its mental illness benefits in 1975. In 1973 mental illness benefits represented 7.4% of all payments under the Blues plan and 12% under the Aetna plan. The benefit for mental illness treatment under the Blues averaged $12.52 per person covered and was 7.3% of the total benefits for all conditions. Younger enrollees and their spouses tended to receive mental illness benefits primarily for outpatient treatment and children and older adults for hospitalization. These data raise key questions for claims review and peer review activities.
Case 34-1971
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Newton E. Hyslop, Robert E. Scully
Journal: New England Journal of Medicine (1971)

Presentation of CaseA 63-year-old woman was admitted to the hospital because of fever.Four years before admission she underwent a right radical mastectomy because of carcinoma of the breast; all 15 excised lymph nodes contained carcinoma, and she was given radiation treatment in a dose of 4500 rads. Three years before entry a metastatic nodule appeared in the mastectomy scar, and further radiation treatment was given, with poor response; diethylstilbestrol was without benefit, and excision of the involved area of skin together with bilateral oophorectomy was performed. One year later radiation treatment was again given because of recurrent skin . . .
Epididymal Metastasis of Prostate Cancer Detected With 68Ga-PSMA-PET/CT
Authors: Sebastian Serfling, Achim Luther, Aleksander Kosmala, Christina Bluemel
Journal: Clinical Nuclear Medicine (2016)

Here, we report on a 73-year-old man with a biochemical relapse (PSA level, 1.1 ng/mL) 8 years after radical prostatectomy and radiotherapy. Four years after primary diagnosis, a bilateral subcapsular orchiectomy was performed for endogen androgen deprivation. Physical examination and transrectal ultrasound did not show any suspicious finding. Subsequently, a Ga-PSMA-PET/CT was performed and revealed a very rare epididymal metastasis. After surgery, the PSA level decreased to less than 0.07 ng/mL, and 4 months later, the patient is still tumor free.